Last updated: December 31, 2024
Introduction to ANDRODERM
ANDRODERM, a testosterone transdermal patch, was a significant player in the market for testosterone replacement therapy. However, in November 2023, AbbVie’s Allergan announced the discontinuation of ANDRODERM, marking the end of this product's availability in the market[1].
Historical Market Context
Before its discontinuation, ANDRODERM was part of a growing market for transdermal drug delivery systems. The global transdermal drug delivery systems market was valued at USD 66.20 billion in 2023 and is expected to grow at a CAGR of 11.9% from 2024 to 2030[1].
Segment Analysis: Testosterone Replacement Therapy
The hormone segment, particularly testosterone replacement therapy, has been a key area of growth within the transdermal drug delivery market. The demand for testosterone replacement therapies has been driven by the increasing prevalence of conditions such as hypogonadism and the growing awareness of men's health issues.
Regional Market Performance
North America, particularly the U.S., has been a dominant region for transdermal drug delivery systems, including ANDRODERM. The U.S. market was valued at USD 30.31 billion in 2022 and is expected to grow at a CAGR of 11.4% from 2023 to 2030. Factors such as favorable reimbursement scenarios, advanced healthcare infrastructure, and a significant focus on research and development have contributed to this growth[3].
Impact of Discontinuation
The discontinuation of ANDRODERM is expected to create a gap in the market for testosterone transdermal patches. This gap could be filled by other existing or upcoming products. For instance, companies like Acerus Pharmaceuticals, with their product NATESTO®, are positioned to capture a larger market share in the testosterone replacement therapy segment. NATESTO® has shown strong efficacy and safety profiles, making it a viable alternative for patients who were previously using ANDRODERM[5].
Market Projections and Opportunities
Despite the discontinuation of ANDRODERM, the overall market for testosterone replacement therapies remains robust. Here are some key projections and opportunities:
Growing Demand
The demand for testosterone replacement therapies is expected to continue growing due to the increasing prevalence of hypogonadism and other related conditions. Approximately 14 million men in the U.S. may have hypogonadism, representing a significant market opportunity[5].
Technological Advancements
Ongoing technological advancements in transdermal drug delivery systems are expected to drive market growth. Innovations such as abuse-deterrent technologies and improved delivery mechanisms are likely to attract more patients and healthcare providers[1].
Competitive Landscape
Companies like AbbVie, despite the discontinuation of ANDRODERM, and Acerus Pharmaceuticals are well-positioned to benefit from the growing demand for testosterone replacement therapies. New entrants and existing players are likely to invest heavily in research and development to capture market share[1][5].
Sales Projections
While specific sales projections for ANDRODERM are no longer relevant due to its discontinuation, the broader market for testosterone replacement therapies is expected to see significant growth.
- Market Size: The U.S. market for testosterone replacement therapies, including transdermal patches, is part of a larger market projected to reach USD 71.63 billion by 2030[3].
- Growth Rate: The CAGR for the U.S. transdermal drug delivery system market is expected to be around 11.4% from 2023 to 2030[3].
- Prescription Volume: The number of prescriptions for testosterone replacement therapies is expected to increase, with estimates suggesting a potential market size ranging from $2 billion to $5 billion in the U.S. alone[2].
Key Takeaways
- Discontinuation Impact: The discontinuation of ANDRODERM creates a market gap that other products can fill.
- Growing Demand: The demand for testosterone replacement therapies is expected to continue growing.
- Technological Advancements: Innovations in transdermal drug delivery systems will drive market growth.
- Competitive Landscape: Companies like Acerus Pharmaceuticals are well-positioned to capture market share.
- Market Projections: The broader market for transdermal drug delivery systems is expected to grow significantly.
FAQs
-
Why was ANDRODERM discontinued?
- ANDRODERM was discontinued by AbbVie’s Allergan in November 2023, but the specific reasons for this decision were not detailed in the available sources.
-
What are the alternatives to ANDRODERM?
- Alternatives include other testosterone transdermal patches and products like NATESTO® from Acerus Pharmaceuticals.
-
How is the market for testosterone replacement therapies expected to grow?
- The market is expected to grow significantly, driven by increasing demand and technological advancements, with a projected CAGR of 11.4% in the U.S. from 2023 to 2030.
-
Which regions are expected to drive the growth of the transdermal drug delivery systems market?
- North America, particularly the U.S., and the Asia Pacific region are expected to be key drivers of market growth.
-
What are the key factors driving the growth of the transdermal drug delivery systems market?
- Factors include increasing prevalence of chronic diseases, favorable reimbursement scenarios, technological advancements, and growing healthcare spending in emerging economies.
Sources
- Grandview Research - Transdermal Drug Delivery System Market Size Report, 2030
- Seeking Alpha - 2023 Could Be Big For Testosterone: AbbVie And ANI Best Positioned To Benefit
- Grandview Research - U.S. Transdermal Drug Delivery System Market Report, 2030
- Business Wire - Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2020 to 2026
- Acerus Pharmaceuticals - Acerus Corporate Deck November 2020
